Personalized CZA‐ATM dosing against an XDR <i>E. coli</i> in liver transplant patients; the application of the in vitro hollow fiber system
The HFS provides a dynamic culture solution for informing individualized medicine by testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient's infection. .
Authors
- Timothy D. McHugh (ORCID: https://orcid.org/0000-0003-4658-8594)
- David Nasralla (ORCID: https://orcid.org/0000-0001-5531-3387)
- Michael D. Spiro (ORCID: https://orcid.org/0000-0002-3201-471X)
- Frank Kloprogge (ORCID: https://orcid.org/0000-0001-7213-4559)
- Jonathan R. Potts (ORCID: https://orcid.org/0000-0002-8564-2904)
- Zahra Sadouki (ORCID: https://orcid.org/0000-0003-3332-7811)
- Satheesh Iype (ORCID: https://orcid.org/0000-0002-2822-3017)
- Emmanuel Wey (ORCID: https://orcid.org/0000-0003-2985-9524)
- Alan Williams (ORCID: https://orcid.org/0000-0002-7928-0353)
Institutions
- Royal Free London NHS Foundation Trust (GB)
- The Royal Free Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1111/tid.14396
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- UK Research and Innovation
- University College London
- Shionogi
- Medical Research Council